1. Pharmacovigilance Risk Assessment Committee Rules of Procedure.2013.http://www.ema.europa.eu/docs/en_GB/document_library/Other/2013/03/WC500139609.pdf.Accessed August 14 2018.
2. European Medicines Agency(EMA).European medicines regulatory network.http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000671.jsp&mid=WC0b01ac05809f8ed0. Accessed August 14 2018.
3. European Medicines Agency(EMA).Human regulatory.https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/good-pharmacovigilance-practices. Accessed October 3 2019.
4. Dear Health Care Provider Letters: Improving Communication of Important Safety Information.2014.https://www.fda.gov/downloads/drugs/guidances/ucm233769.pdf. Accessed August 14 2018.
5. Impact of Safety-Related Regulatory Action on Clinical Practice